ArQule Inc (ARQL):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ArQule Inc (ARQL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10077
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ArQule Inc (ArQule) is a development stage clinical biotechnology company. It carries out discovery and development of next-generation, small molecule therapeutics for the treatment of various types of cancer. ArQule develops its oncology product candidates through novel approaches including activated checkpoint therapy platform and c-met survival protein platform. Its lead product candidate, ARQ 197 (tivantinib), an inhibitor of the c-Met receptor tyrosine kinase, is undergoing clinical-stage development. The other product pipeline of the company includes ARQ 087 is a multi-kinase inhibitor, ARQ 092 is an Akt inhibitor, ARQ 751 is a next-generation inhibitor of Akt, ARQ 761 is an activator of the damage response pathway, ARQ 531 is a B-cell malignancies and ARQ 087 is an inhibitor of fibroblast growth factor receptor. ArQule is headquartered in Burlington, Massachusetts, the US.

ArQule Inc (ARQL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ArQule Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
Partnerships 12
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Licensing Agreements 13
Basilea Pharma Enters into Licensing Agreement with ArQule 13
Roivant Sciences Enters into Licensing Agreement with ArQule 14
Equity Offering 15
ArQule Raises USD70 Million in Public Offering of Shares 15
ArQule to Raise Funds in Secondary Offering of Shares 17
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18
ArQule to Raise Up to USD30 Million in Issue of Shares 19
ArQule Raises USD15.3 Million in Private Placement of Shares 20
ArQule Completes Public Offering Of Common Stock For US$60 Million 21
ArQule Inc – Key Competitors 23
ArQule Inc – Key Employees 24
ArQule Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Oct 31, 2018: ArQule reports third quarter 2018 financial results 26
Aug 01, 2018: ArQule Reports Second Quarter 2018 Financial Results 28
May 07, 2018: ArQule Reports First Quarter 2018 Financial Results 30
Nov 09, 2017: ArQule Reports Third Quarter 2017 Financial Results 32
Aug 04, 2017: ArQule Reports Second Quarter 2017 Financial Results 34
May 03, 2017: Arqule Reports First Quarter 2017 Financial Results 35
Mar 07, 2017: ArQule Reports Fourth Quarter and Full Year 2016 Financial Results 36
Corporate Communications 38
May 24, 2018: ArQule Announces Two Key Appointments 38
Product News 39
06/07/2017: ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases 39
06/03/2017: ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology Annual Meeting 40
05/17/2017: ArQule to Present Clinical Data on ARQ-087 at the 2017 American Society of Clinical Oncology Annual Meeting 41
03/15/2018: ArQule to Present Data on Derazantinib 42
Product Approvals 43
Nov 01, 2017: FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome 43
Clinical Trials 44
Mar 15, 2018: ArQule to Provide Update on ARQ 751 44
Nov 21, 2017: ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma 45
Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 46
Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 47
May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 48
May 17, 2017: ArQule to Present Clinical Data on ARQ-092 at the 2017 American Society of Clinical Oncology Annual Meeting 49
May 17, 2017: ArQule to Present Clinical Data on ARQ-761 at the 2017 American Society of Clinical Oncology Annual Meeting 50
Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
ArQule Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ArQule Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ArQule Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ArQule Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ArQule Raises USD15.7 Million in Private Placement of Common Stock 11
ArQule Enters into Co-Development Agreement with National Human Genome Research Institute for ARQ 092 12
Basilea Pharma Enters into Licensing Agreement with ArQule 13
Roivant Sciences Enters into Licensing Agreement with ArQule 14
ArQule Raises USD70 Million in Public Offering of Shares 15
ArQule to Raise Funds in Secondary Offering of Shares 17
ArQule Raises USD9.5 Million in Private Placement of Preferred Shares and Warrants 18
ArQule to Raise Up to USD30 Million in Issue of Shares 19
ArQule Raises USD15.3 Million in Private Placement of Shares 20
ArQule Completes Public Offering Of Common Stock For US$60 Million 21
ArQule Inc, Key Competitors 23
ArQule Inc, Key Employees 24

List of Figures
ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ArQule Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ArQule Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[ArQule Inc (ARQL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nestle Health Science SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Nestle Health Science SA (Nestle Health), a subsidiary of Nestle SA, is a health science company that manufactures nutritional and medicinal products derived from botanical plants. The company provides nutritional therapies for chronic conditions related to gastrointestinal diseases, aging p …
  • Compania Espanola de Petroleos SAU:企業の戦略的SWOT分析
    Compania Espanola de Petroleos SAU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Atlantic Power Corporation:発電所・企業SWOT分析
    Atlantic Power Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • HTP Korcula d.d.:企業の戦略・SWOT・財務分析
    HTP Korcula d.d. - Strategy, SWOT and Corporate Finance Report Summary HTP Korcula d.d. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Salzgitter AG:企業の戦略・SWOT・財務分析
    Salzgitter AG - Strategy, SWOT and Corporate Finance Report Summary Salzgitter AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Chesnara plc:企業の戦略・SWOT・財務情報
    Chesnara plc - Strategy, SWOT and Corporate Finance Report Summary Chesnara plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • FLX Bio Inc-製薬・医療分野:企業M&A・提携分析
    Summary FLX Bio Inc (FLX Bio) focuses on the discovery, development and commercialization of novel immuno-oncology agents. The company’s pipeline product, FLX925 is a drug targeting the FLT3 mutations which is found in patients with acute myeloid leukemia (AML). FLX925 simultaneously targets a secon …
  • Maximus Inc (MMS):企業の財務・戦略的SWOT分析
    Maximus Inc (MMS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kosmos Energy Ltd (KOS):企業の財務・戦略的SWOT分析
    Kosmos Energy Ltd (KOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • NuScale Power LLC:企業の戦略的SWOT分析
    NuScale Power LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Capitol Federal Financial, Inc:企業の戦略・SWOT・財務情報
    Capitol Federal Financial, Inc - Strategy, SWOT and Corporate Finance Report Summary Capitol Federal Financial, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • The Medicines Company (MDCO):製薬・医療:M&Aディール及び事業提携情報
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle …
  • AdvanDx Inc:医療機器:M&Aディール及び事業提携情報
    Summary AdvanDx Inc (AdvanDx), a subsidiary of OpGen Inc is a healthcare solution provider that offers rapid and accurate molecular diagnostic tests for identification of pathogens causing critical infections in hospitalized patients. The company operates molecular testing of positive blood cultures …
  • Petro Matad Ltd (MATD):石油・ガス:M&Aディール及び事業提携情報
    Summary Petro Matad Ltd (Petro Matad) is an oil and gas company that develops and operates oil and gas exploration properties. The company’s upstream oil and gas exploration asset base includes Block IV, Block XX, and Block V. Its Block XX is located in the far eastern part of Mongolia producing oil …
  • Meiji Co Ltd:企業の戦略・SWOT・財務分析
    Meiji Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Meiji Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Even Construtora E Incorporadora Sa:企業の戦略・SWOT・財務分析
    Even Construtora E Incorporadora Sa - Strategy, SWOT and Corporate Finance Report Summary Even Construtora E Incorporadora Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Douglas GmbH:企業の戦略・SWOT・財務情報
    Douglas GmbH - Strategy, SWOT and Corporate Finance Report Summary Douglas GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Co-Diagnostics Inc:企業の製品パイプライン分析2018
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …
  • Sempra U.S. Gas & Power LLC-エネルギー分野:企業M&A・提携分析
    Summary Sempra U.S. Gas & Power, LLC (Sempra US), a subsidiary of Sempra Energy, an energy solution provider, is a clean power solutions developer. It develops, designs, constructs and operates renewable energy and natural gas solutions, with a focus on zero and low emission fuels. The company owns …
  • Alternative Networks Plc:戦略・SWOT・企業財務分析
    Alternative Networks Plc - Strategy, SWOT and Corporate Finance Report Summary Alternative Networks Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆